Sanofi-aventis announces Changes to Executive Committee

Sanofi-aventis announces Changes to Executive Committee
02/11/2009 14:37 (05:53 minutes ago)
 
The FINANCIAL -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced on November 2 a number of changes to its Executive Committee. In a message to employees, Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis, detailed the new appointments and his new management team.
 

In order to manage the Group's new business activities beyond pharmaceuticals, Hanspeter SPEK is appointed President, Global Operations. He was previously Executive Vice President, Pharmaceutical Operations.


Given the strategic importance of the Transforming R&D program, Marc CLUZEL is appointed Executive Vice President, Research & Development. He was previously Senior Vice President, Research & Development.


Finally, due to the essential role of Sanofi Pasteur, the vaccines worldwide leader, Wayne PISANO, Senior Vice President, Vaccines, joins the Group's Executive Committee.


As from today, the Executive Committee, chaired by Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis, meets twice a month and comprises the following members :


- Marc CLUZEL, Executive Vice President, Research & Development
- Jérôme CONTAMINE, Executive Vice President, Chief Financial Officer
- Laurence DEBROUX, Senior Vice President, Chief Strategic Officer
- Karen LINEHAN, Senior Vice President, Legal Affairs and General Counsel
- Philippe LUSCAN, Senior Vice President, Industrial Affairs
- Wayne PISANO, Senior Vice President, Vaccines
- Roberto PUCCI, Senior Vice President, Human Resources
- Hanspeter SPEK, President, Global Operations.


Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis declared: " I am extremely pleased to work with this international team who gathers competence, energy and experience to transform sanofi-aventis into a global diversified healthcare leader".

 

Investegate is the most comprehensive online source of announcements from UK quoted companies, allowing you to view all regulatory and other published information in one place. trustnet investegate datafeeds fundlistings

 

Online Alerts E-Mail Alerts Top Announcements  Annual Reports Free Brochures About Us
Latest FTSE-100 FTSE-250 AIM techMARK Company Category Sector Archive
Search by:   Keyword Company EPIC / TIDM SEDOL / ISIN     search 
Sanofi Aventis  Monday 2 November, 2009
 
10:25A - Sanofi-aventis announces Changes to Executive C...
print     mail a friend     more announcements
 
TRADE HERE


PR Newswire/Les Echos/

Sanofi-aventis Press Release

Sanofi-aventis announces Changes to Executive Committee

Paris, France - November 2, 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY)
announced today a number of changes to its Executive Committee. In a message to
employees, Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis,
detailed the new appointments and his new management team.

In order to manage the Group's new business activities beyond pharmaceuticals,
Hanspeter SPEK is appointed President, Global Operations. He was previously
Executive Vice President, Pharmaceutical Operations.

Given the strategic importance of the Transforming R&D program, Marc CLUZEL is
appointed Executive Vice President, Research & Development. He was previously
Senior Vice President, Research & Development.

Finally, due to the essential role of Sanofi Pasteur, the vaccines worldwide
leader, Wayne PISANO, Senior Vice President, Vaccines, joins the Group's
Executive Committee.

As from today, the Executive Committee, chaired by Christopher A. Viehbacher,
Chief Executive Officer of sanofi-aventis, meets twice a month and comprises the
following members :

  - Marc CLUZEL,       Executive Vice President, Research & Development
  - Jérôme CONTAMINE,  Executive Vice President, Chief Financial Officer
  - Laurence DEBROUX,  Senior Vice President, Chief Strategic Officer
  - Karen LINEHAN,     Senior Vice President, Legal Affairs and General Counsel
  - Philippe LUSCAN,   Senior Vice President, Industrial Affairs
  - Wayne PISANO,      Senior Vice President, Vaccines
  - Roberto PUCCI,     Senior Vice President, Human Resources
  - Hanspeter SPEK,    President, Global Operations.

Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis declared: "
I am extremely pleased to work with this international team who gathers
competence, energy and experience to transform sanofi-aventis into a global
diversified healthcare leader".

About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and
distributes therapeutic solutions to improve the lives of everyone.
Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi-aventis www.sanofi-aventis.com
Media Relations: Tel. : (+) 33 1 53 77 44 50 - E-mail : [email protected]
Investor Relations : Tel. : (+) 33 1 53 77 45 45 -
E-mail : [email protected]
                     
The content and accuracy of news releases published on this site and/or
distributed by PR Newswire or its partners are the sole responsibility of the
originating company or organisation. Whilst every effort is made to ensure the
accuracy of our services, such releases are not actively monitored or reviewed
by PR Newswire or its partners and under no circumstances shall PR Newswire or
its partners be liable for any loss or damage resulting from the use of such
information. All information should be checked prior to publication.

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.